In 2017, Abul-Husn et al. firstly reported that the loss of function variant HSD17B13:TA mitigates the risk of liver disease progression conferred by carriage of PNPLA3 I148M among NAFLD patients [6]. The gene discussed is PNPLA3; the disease is metabolic dysfunction-associated steatotic liver disease.